TrialThe Lancet. Haematology2022
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Shehu U Abdullahi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
56 papers cite it
this paperpooled ittrialcites it